GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Shiller PE Ratio

CASI Pharmaceuticals (FRA:ENM) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CASI Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for CASI Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Shiller PE Ratio Chart

CASI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CASI Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CASI Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, CASI Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Shiller PE Ratio falls into.



CASI Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CASI Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, CASI Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.653/115.2271*115.2271
=-0.653

Current CPI (Mar. 2024) = 115.2271.

CASI Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.442 98.200 -0.519
201409 -5.975 98.900 -6.961
201412 -0.162 99.000 -0.189
201503 -0.554 99.900 -0.639
201506 -0.535 99.500 -0.620
201509 -0.445 100.500 -0.510
201512 -0.459 100.600 -0.526
201603 -0.359 102.200 -0.405
201606 -0.712 101.400 -0.809
201609 -0.267 102.400 -0.300
201612 -0.421 102.600 -0.473
201703 -0.280 103.200 -0.313
201706 -0.356 103.100 -0.398
201709 -0.252 104.100 -0.279
201712 -0.676 104.500 -0.745
201803 -0.405 105.300 -0.443
201806 -0.599 104.900 -0.658
201809 -0.857 106.600 -0.926
201812 -0.879 106.500 -0.951
201903 -0.797 107.700 -0.853
201906 -1.416 107.700 -1.515
201909 -0.908 109.800 -0.953
201912 -1.170 111.200 -1.212
202003 -0.814 112.300 -0.835
202006 -0.799 110.400 -0.834
202009 -1.189 111.700 -1.227
202012 -0.962 111.500 -0.994
202103 -0.924 112.662 -0.945
202106 -0.415 111.769 -0.428
202109 -0.621 112.215 -0.638
202112 -0.345 113.108 -0.351
202203 -0.563 114.335 -0.567
202206 -0.530 114.558 -0.533
202209 -0.384 115.339 -0.384
202212 -1.359 115.116 -1.360
202303 -0.420 115.116 -0.420
202306 -0.711 114.558 -0.715
202309 -0.328 115.339 -0.328
202312 -0.422 114.781 -0.424
202403 -0.653 115.227 -0.653

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CASI Pharmaceuticals  (FRA:ENM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CASI Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CASI Pharmaceuticals (FRA:ENM) Business Description

Traded in Other Exchanges
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines